Skip to main content

Merck KGaA targets higher growth

13th September 2021

Submitted by:

Andrew Warmington

At its virtual capital markets day on 9 September, Merck KGaA announced that it aims to increase group sales by 6%/year to about €25 billion/year by 2025. To this end, investment, which will increase by 50% in the  years 2021-2025 compared to 2016-2020.

“We will continue to consistently and purposefully invest in areas that make us strong,” said CEO and executive board chair Belén Garijo (pictured). Merck will also seek targeted acquisitions, which are most likely to be small to medium-sized.

About 80% of planned sales growth is to come from the ‘Big 3’ businesses, which include the Semiconductor Solutions business within the Electronics business sector. The others are the Process Solutions business within the Life Science sector and new products from the Healthcare sector. These areas will receive over 70% of the investment.

Under the newly announced ‘Level Up’ growth programme, planned growth for Electronics is revised upwards from 3-4%/year to 3-6%/year from 2021 to 2025. About 80% of this will come from Semiconductor Solutions. Electronics will address four mutually reinforcing key priorities, it said: scale, technology, portfolio, and people and capabilities. It is thus investing in digital business models and data analysis competencies, as well as more capacities near to its customers, especially in the US, Korea, Taiwan, China and Germany.

The medium-term growth forecast for Life Science has also been revised upwards, from 6-9%/year to 7-10%/year. Much of this will be driven by the Bioprocessing business within Process Solutions. “Merck is also planning to expand the business with services for the contract manufacturing and development of therapies in a targeted manner, both for established and new modalities,” it said.

In Healthcare, Merck expects medium-term average annual organic sales growth in the mid single-digit percentage range. New products should contribute around 75% to growth in the years up to 2025. 

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington